Skip to main content
RENALYTIX PLC logo

RENALYTIX PLC — Investor Relations & Filings

Ticker · RENX ISIN · GB00BYWL4Y04 LEI · 213800NTOH3FK3WER551 IL Human health and social work activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2024-05-09 Report Publication Anno…
Country GB United Kingdom
Listing IL RENX

About RENALYTIX PLC

https://renalytix.com/

Renalytix is a diagnostics company that develops artificial intelligence-enabled solutions for the clinical management of kidney disease. Its flagship product, KidneyIntelX.dkd™, is an FDA-authorized blood test for adults with type 2 diabetes and early-stage chronic kidney disease. The test utilizes a proprietary bioprognostic™ methodology to analyze biomarkers and clinical data, predicting the risk of a progressive decline in kidney function over a five-year period. This risk assessment enables clinicians to identify high-risk patients and implement targeted, guideline-recommended treatments to slow disease progression and improve outcomes.

Recent filings

Filing Released Lang Actions
Notice of Q3 Results
Report Publication Announcement Classification · 99% confidence The document is a formal announcement disseminated via RNS (National Storage Mechanism), which is the news service of the London Stock Exchange, and is approved by the FCA. The core content announces that Renalytix plc will report its financial results for the third quarter of fiscal year 2024 on a specific future date (May 15, 2024) and will host a conference call. This is not the actual financial report (ER or IR), nor is it a transcript (CT) or a detailed presentation (IP). It is an announcement about the publication of a report and the associated call. According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). Since it specifically details the timing of an earnings report release and call, RPA is the most precise fit over the general RNS fallback.
2024-05-09 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the RNS Number (8938M) and the header 'RNS Number : 8938M'. The content is a 'TR-1: Standard form for notification of major holdings', which details changes in voting rights held by a shareholder (Polar Capital LLP) in the issuer (Renalytix PLC). This type of mandatory disclosure regarding significant changes in share ownership thresholds falls directly under the definition of Major Shareholding Notification. The code for this is MRQ.
2024-05-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the RNS Number (4878M) and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the percentage of voting rights held by an entity (CVI Investments, Inc.) crossing a threshold. This directly corresponds to the definition of a Major Shareholding Notification.
2024-04-30 English
Form 8.3 - Renalytix plc
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 8.3' and concerns 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' under 'Rule 8.3 of the Takeover Code'. This form relates to insider dealings or significant ownership changes during a takeover scenario. This type of filing, which reports personal share transactions by executives or major shareholders, aligns most closely with the 'Director's Dealing' category (DIRS), although it is specifically mandated by the Takeover Code. Since 'DIRS' covers 'Report of personal share transactions by company directors and executives (insider trades)', and this is a mandatory disclosure of a 15.53% interest and recent share receipt related to a potential offer, DIRS is the most appropriate classification among the provided options. It is not a general regulatory filing (RNS) because it is highly specific to insider dealing rules during a takeover context.
2024-04-29 English
Admission of the First Tranche Placing Shares
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated April 29, 2024. It announces the 'Admission of the First Tranche Placing Shares' following previous fundraising announcements. The content is a formal regulatory announcement disseminated via RNS (the news service of the London Stock Exchange). While it discusses capital structure changes (issuance of shares), the primary function of this specific document is to serve as a general regulatory disclosure on the LSE's news service, rather than being a detailed Capital/Financing Update (CAP) or Share Issue announcement (SHA) itself, especially given the RNS header and the nature of the announcement being about admission to trading. Since it is a standard, non-specific regulatory announcement distributed via RNS that doesn't fit perfectly into the other specific categories (like ER, 10-K, DIV, etc.), the most appropriate classification is the general regulatory filing fallback category.
2024-04-29 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number : 2943M' and contains the standard format for a 'NOTIFICATION OF MAJOR HOLDINGS'. This type of filing reports changes in significant share ownership thresholds. This directly corresponds to the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-04-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.